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in diagnosis and staging of primary ocular and orbital tumorsKa-Hoi Hui, BS a,b; Margaret L. Pfeiffer, BA a,b; Bita Esmaeli, MD a,⇑AbstractAccurate and reliable staging methods are crucial for optimal care of patients with ocular and orbital malignancies. Positron emis-
sion tomography/computed tomography (PET/CT) has recently emerged as a staging tool in the field of ophthalmic oncology. For
detecting primary ocular or orbital lesions, PET/CT does not seem to provide an advantage over clinical ophthalmologic exami-
nation or conventional imaging studies such as CT or magnetic resonance imaging of the orbit. However, PET/CT may detect dis-
tant metastatic lesions that conventional imaging studies miss. For orbital and ocular adnexal lymphoma, use of PET/CT has been
proven to be feasible and is now accepted both as a standard part of the initial staging work-up and for the assessment of
response to therapy. For other ophthalmic tumors, PET/CT seems most appropriate for advanced metastatic tumors of the orbit,
eyelid, and eye, for which the detection of distant metastasis with 1 comprehensive study may be preferable to performing multi-
ple CT scans with contrast.
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The prognosis of patients with a newly diagnosed primary
ocular or orbital malignancy depends on the tumor’s stage.
Cancer staging characterizes the size, location, and histo-
pathologic features of the primary tumor and the degree of
regional and distant metastasis associated with the primary
tumor. Accurate and reliable staging methods are crucial be-
cause clinicians must tailor treatment options specifically to
the tumor stage. Whole body positron emission tomogra-
phy/computed tomography (PET/CT) has been widely used
in the staging of lymphoma, cutaneous melanoma, colorectal
cancer, and other gastrointestinal malignancies.1–3 However,
the use of PET/CT in the field of ophthalmic oncology has
emerged only recently. PET/CT has shown promise in provid-Peer review under responsibility
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orbital tumors, all of which facilitate selection of the most
appropriate treatment options.4 In this review, we will ex-
plore the significance of PET/CT in the diagnosis and staging
of primary ocular and orbital tumors. PET/CT may also detect
metastases in the globe, orbit, or ocular adnexae from pri-
mary tumors at other sites, but this review focuses on the
use of PET/CT for the diagnosis and staging of primary ocular
and orbital malignancies only.
Methods
We carried out a PubMed search of all articles on the clin-
ical usefulness of PET/CT in primary ocular and orbital tumors
published in English using the keyword ‘‘PET/CT’’, staging,Production and hosting by Elsevier
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by a date range. We conducted additional searches for ‘‘PET/
CT’’ and the following tumors: ‘‘ocular lymphoma’’, ‘‘orbital
lymphoma’’, ‘‘uveal melanoma’’, ‘‘choroidal melanoma’’,
‘‘conjunctival melanoma’’, ‘‘cutaneous eyelid melanoma’’,
‘‘sebaceous carcinoma’’, ‘‘squamous cell carcinoma’’, ‘‘Mer-
kel cell carcinoma’’, retinoblastoma, and adenoid cystic
carcinoma.Results
Principles and technique of PET/CT
PET has been widely used in whole body imaging of neo-
plasms. PET demonstrates areas of high uptake of glucose-la-
beled radiotracer. PET provides functional data by measuring
the distribution of administered tracer, but it has poor spatial
resolution and provides little information about anatomic
structures. CT provides precise anatomic localization of
abnormalities but does not provide information about meta-
bolic abnormalities. Combined PET/CT integrates the meta-
bolic information provided by PET with the anatomic
information provided by CT and offers several advantages
over the use of separate PET and CT: decreased image acqui-
sition time, increased accuracy of tumor localization, in-
creased likelihood of staging in a single step, and removal
of opportunities for human error in visually combining sepa-
rate images.5–7
In FDG PET/CT, 18-fluoro-2-deoxy-D-glucose (FDG), a glu-
cose analogue, is converted into FDG-6-phosphate, which is
unable to undergo glycolysis and is dephosphorylated at a
reduced rate. Since tumor cells have a higher affinity for glu-
cose than normal cells and use glycolysis as their primary
mechanism of metabolism, FDG accumulates in tumor cells
and can be detected by the scanner.8 Patients are required
to fast for at least 4–6 h before the injection of FDG to reduce
physiologic glucose utilization and insulin levels to baseline.
The acceptable fasting glucose level is 80–160 mg/dl.9 FDG
is then injected intravenously at a dose calculated according
to the following formula: weight of the patient in kilograms
multiplied by the target dose per 70 kg.10,11 After a 45- to
60-min uptake period, CT is performed using a multidetector
helical CT scanner. Typically, the body is imaged from head
to toe or head to thigh.
The integration of PET and CT images can be accom-
plished by software or hardware fusion. Movement of internal
organs, scanner bed profiles, and patient position limit the
accuracy of software fusion. A combined PET/CT scanner,
the ‘‘hardware fusion’’, overcomes these limitations.12 The
data are analyzed quantitatively by measuring the standard-
ized uptake value (SUV), which is defined as the ratio of the
activity within the tissue (Bq/ml) to the injected dose (Bq) di-
vided by the body weight (kg) (activity/[injected dose/body
weight]).9 The SUV is expressed as its maximum. Currently,
no standard exists for the cutoff value of SUV used to differ-
entiate benign (metabolically inactive) from malignant
(metabolically active) lesions, but authors have used maxi-
mum SUV values of 2.5 and 4 for choroidal melanoma for this
purpose.9,11 In 16 patients with ocular adnexal lymphoma
(OAL), the mean SUV was 6.5.13 The resulting images are
also analyzed qualitatively for the presence of local
tumors, regional nodal metastases, and distant metastases.False-positive findings can be differentiated from true posi-
tive findings on the basis of tumor location, symmetry, and
clinical history.Role of PET/CT in uveal melanoma
Uveal melanoma is the most common primary intraocular
malignancy in adults, with a reported incidence of 5–7 cases
per million individuals per year in North America.14 The
5-year survival rate for patients with uveal melanoma con-
fined to the eye is 81.6%, and the 1-year survival rate for pa-
tients with uveal melanoma with systemic metastases is
13%.15,16 Uveal melanoma has a unique metastatic pattern
of the liver as the first and predominant site of metastasis
in over 70% of patients.17,18
The Collaborative Ocular Melanoma Study Group estab-
lished a protocol for the detection of metastatic choroidal
melanoma. Components of the protocol include physical
examination, hematologic analyses including complete blood
cell count and liver function tests (LFTs), chest radiography,
ophthalmic ultrasonography, and fluorescein angiogra-
phy.10,19,20 If indicated, fine needle aspiration or core needle
liver biopsies can be performed for disease confirmation.20
Studies have shown that although liver ultrasonography,
LFTs, and chest radiography have high specificity in the
detection of metastatic uveal melanoma, they have low sen-
sitivity.21,22 Hematologic tests have been shown to have both
low sensitivity and low specificity.21 Eskelin et al. reported
that LFTs and abdominal ultrasonography accurately de-
tected liver metastases in only 59% of asymptomatic patients
with liver metastases and that chest radiography detected
pulmonary metastases in only 2% of patients with pulmonary
metastases.23
Given these limitations of routine surveillance methods,
PET/CT has the potential to provide a substantial benefit.
Reddy et al. found that PET/CT was able to detect the met-
abolic activity of choroidal melanoma and was most effective
in detecting American Joint Committee on Cancer T3 and
larger choroidal melanomas.10 However, these investigators
concluded that PET/CT was not superior to standard clinical
protocol in diagnosing choroidal melanoma. In addition,
PET/CT was unable to differentiate between small melano-
mas and suspicious choroidal nevi. A positive correlation be-
tween SUV and the size of choroidal melanoma was found,
but there was no significant correlation between SUV and
other factors, such as age, sex, or tumor location.10 In a dif-
ferent study, PET/CT was reported to be able to detect small
uveal melanomas despite the limited spatial resolution due to
the small physical size of the detectors and diameter of the
PET detector ring.24
Whole body PET/CT has been shown to play a significant
role in detecting regional and distant metastases from uveal
melanoma. Klingenstein et al. reported using PET/CT to cor-
rectly show metastases in 12 of 12 patients with primary uveal
melanoma.25 Kurli et al. reported 100% sensitivity and 100%
specificity of PET/CT in the identification of hepatic metasta-
sis compared to 12.5% sensitivity of LFTs.20 PET/CT has iden-
tified hepatic metastases in patients with normal LFTs and
hepatic metastases that could not be detected by abdominal
ultrasonography because of hemorrhage and elaborate tu-
mor mass.25 PET/CT is also useful in identifying extrahepatic
metastases, especially osseous metastases.20 For osseous le-
Figure 1. Baseline PET in a patient with lacrimal gland MALT lymphoma
shows a focal area of increased FDB uptake in the right arm. An MRI of
the upper extremity was subsequently done and confirmed the presence
of a lesion in the biceps muscle which upon biopsy proved to be a focus of
lymphoma.
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nant, PET/CT was able to make the distinction.20
In addition to being used for staging of uveal melanoma,
PET/CT has been explored as a noninvasive method to assess
the risk of metastasis from uveal melanoma. Finger et al.
found that there was a positive correlation between higher
SUV and larger anterior epitheloid-cell uveal melanoma.
Since the largest tumor diameter and cell type are among
the widely accepted risk factors for metastasis and shown
by the Collaborative Ocular Melanoma Study to be statisti-
cally significant risk factors, Finger et al. concluded that
PET/CT may be an effective biomarker for the metastatic po-
tential of uveal melanoma.9
There are studies that call into question the value of PET/
CT in detecting primary uveal melanoma and liver metasta-
ses. Strobel et al. reported that in 13 patients with uveal mel-
anoma with 27 known liver metastases, 16 of 27 liver
metastases were negative on FDG PET/CT, for a false-
negative rate of 59%.26 This is in contrast to similar studies
that have shown no false-negative events.11,20 Furthermore,
Strobel et al. reported significantly lower SUVs for liver
metastases from uveal melanoma (mean value, 3.5) than for
liver metastases from cutaneous melanoma (mean value,
6.6). They concluded that FDG PET/CT lacks sufficient sensi-
tivity for detecting liver metastases from uveal melanoma.
Strobel et al. explained the high false-negative rate in their
study by stating that other studies with no false-negative
events included only patients with positive findings on PET
and not patients with negative findings on PET but suspicious
findings on magnetic resonance imaging (MRI) or CT scans.26
Orcurto et al. reported that MRI was superior to PET/CT in
detecting small liver metastases from uveal melanoma.27
In addition to potentially being useful for identifying
metastases from uveal melanoma, PET/CT may be useful
for evaluation of the response to therapy. PET/CT was found
to be superior to MRI in evaluating treatment response.27
One study showed that SUVs decreased in the primary tumor
site (in the eye) over time following ophthalmic plaque
radiotherapy.28,29Role of PET/CT in orbital and ocular adnexal tumors
Lymphoma
Orbital lymphoma is the most common primary orbital
malignancy in adults.30 Ocular adnexal lymphoma is the term
used in the literature to describe lymphomas involving the or-
bit, eyelid, or conjunctiva or a combination of these anatomic
structures. In a series of patients with OAL of all subtypes at
MD Anderson, regional or distant involvement was present in
25 of 43 patients (58%) on initial presentation, indicated by
stage greater than IE according to the Ann Arbor Staging
System.31 Therefore, thorough systemic staging is critical
for patients who present with OAL. Whole body PET/CT
has become part of standard staging for orbital lymphoma
and OAL and is probably used more widely for these diseases
than for any other tumors of the eye and orbit (Fig. 1).
OAL most commonly arises from the lacrimal gland and
conjunctiva and accounts for approximately 8% of all extran-
odal lymphomas but only 2% of all non-Hodgkin lymphomas.
OAL may present bilaterally in any part of the orbit and can
be either localized to the orbit and adnexal area or associ-
ated with systemic sites of involvement.32 Current modalitiesfor staging of OAL include physical examination, complete
blood cell count, contrast-enhanced CT, MRI, and bone mar-
row biopsy.33 PET/CT has been shown to have higher sensi-
tivity than CT in detecting systemic sites of involvement
from orbital lymphoma and other extranodal lymphomas.32
The most common histologic subtype of OAL, accounting
for approximately 50% to 70% of OALs, is musosa-associated
lymphoid tissue (MALT)-type lymphoma. This is a low-grade
type of B-cell non-Hodgkin lymphoma. In 18% of cases, there
is bilateral orbital or adnexal involvement.34 Suga et al. re-
ported that in patients with MALT lymphoma, PET/CT was
able to detect contralateral orbital lesions as well as gastric
lesions that could not be detected by MRI alone.35 Roe et
al. reported that PET/CT was able to detect OAL in 3 of 4 pa-
tients (75%) with biopsy-proven orbital MALT lymphoma and
systemic lymphoma in 2 of those 4 patients (50%).33 PET/CT
showed 2 sites of false-negative uptake. The authors con-
cluded that PET/CT has value in diagnosing, staging, and
restaging OAL and may help differentiate between atypical
lymphoid hyperplasia, low-grade MALT lymphoma, and more
aggressive forms.
The conjunctiva is a major site for primary and secondary
lymphomas. Matsuo et al. reported the use of PET/CT in
detecting relapse of MALT lymphoma in 4 patients.36 They
concluded that PET/CT was able to detect small and thin
MALT lymphoma lesions in the conjunctiva.
Low-grade lymphomas such as MALT lymphomas typically
have relatively low FDG uptake. Thus, there is an inherent
possibility of false-negative findings on PET/CT, and clinical
correlation is always necessary. However, in 7 patients with
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Anderson, all had FDG-avid lesions on pretreatment PET.13
Follicular lymphoma is the second most common histo-
logic subtype of OAL after MALT lymphoma. Follicular
lymphoma is another form of low-grade B cell lymphoma,
characterized by follicles with centrocytes. At initial diagno-
sis, 42% of patients have systemic involvement outside the
orbital area. PET/CT has been shown to be valuable in esti-
mating the size of the lesion and detecting systemic involve-
ment of follicular lymphoma involving the orbit.37
Retinoblastoma with invasion of the orbit
Radhakrishnan et al. studied the value of PET/CT in the
staging of retinoblastoma with orbital invasion.38 Typical
staging modalities for retinoblastoma are CT or MRI of the
orbit and brain. PET/CT findings were found to be falsely
negative in 2 of 3 patients with International Retinoblastoma
Staging System stage IIIB disease. These investigators re-
ported no significant difference in sensitivity or specificity be-
tween PET/CT staging and routine staging. Furthermore,
they reported that intraocular retinoblastoma was not FDG
avid. However, these investigators also found that PET/CT
may be valuable in assessing retinoblastoma spread to the
central nervous system via extension through the optic nerve.
They found that optic nerve uptake at baseline PET/CT corre-
lated with retinoblastoma extension to the optic nerve.
Radhakrishnan et al. concluded that PET/CT may have value
in determining the prognosis and assessment of response
to treatment in patients with retinoblastoma with invasion
of the orbit.
Eyelid sebaceous carcinoma
Metastases from eyelid sebaceous carcinoma can be de-
tected and diagnosed by various methods, including CT, fine
needle aspiration, and sentinel lymph node biopsy, depend-
ing on the area of metastatic involvement.39 Krishna et al. re-
ported 2 cases that were successfully staged by PET/CT.40 In
the first case, a sebaceous carcinoma of the lower lid, PET/CT
revealed foci of uptake in the submandibular, supraclavicular,
mediastinal, and retroperitoneal nodes. PET/CT has also
been used to successfully stage an unusual primary seba-
ceous carcinoma of the parotid gland.41
Baek et al. analyzed 15 cases of periocular malignancies, 5
of which were sebaceous carcinomas of the upper eyelid.42 In
follow-up evaluation of these 5 sebaceous carcinomas, PET/
CT correctly identified 4 of 4 cases (100%) of regional lymph
node involvement. In 1 case, PET/CT detected a clinically pal-
pable ipsilateral parotid lymph node that went undetected
by contrast-enhanced CT. Histologic analysis of the node fol-
lowing parotidectomy revealed metastatic sebaceous carci-
noma. In 2 more cases in this series, PET/CT more clearly
identified regional lymph nodes later found to contain metas-
tasis than did contrast-enhanced CT alone.
Conjunctival melanoma
Kurli et al. reported on the use of PET/CT in 14 patients
with locally invasive conjunctival melanoma, 13 with a T3 tu-
mor and 1 with a T4 tumor.43 Half of the patients in this series
were imaged with PET/CT at the time of initial diagnosis of
conjunctival melanoma, and half were imaged after treat-
ment with excision with adjuvant cryotherapy and/or chemo-
therapy. In the patient with the T4 conjunctival melanoma,who had PET/CT performed after treatment and who had
no pretreatment PET/CT, PET/CT identified widespread
metastases, including intrahepatic metastases, despite nor-
mal LFTs, and the patient’s disease was appropriately staged
as T4N1M4. PET/CT findings were negative in all 13 patients
with T3 tumors. The authors concluded that PET/CT has a
limited role in staging of conjunctival melanoma during initial
screening but may be valuable for restaging and follow-up. In
an editorial commenting on Kurli et al’s paper, Esmaeli
emphasized the importance of performing pretreatment,
baseline PET/CT in all patients to evaluate whether the pri-
mary tumor is FDG avid,44 something that Kurli et al. did
not do. She furthermore noted that Kurli et al. did not include
pathologic details about each conjunctival melanoma, includ-
ing Breslow thickness, knowledge of which would have
helped predict the tumors’ metastatic potential. Esmaeli
agreed with Kurli et al. that PET/CT has limited efficacy in ini-
tial evaluation of conjunctival melanoma but may be useful in
the evaluation of response to therapy in patients with known
sites of distant metastases.
Baek et al. reported that in follow-up evaluation of 2 pa-
tients with conjunctival melanoma, PET/CT successfully iden-
tified regional nodal metastases.42 After parotidectomy,
radical neck dissection, and maxillectomy, the first patient
had negative findings on PET/CT at 12 months’ follow-up.
After parotidectomy and nodal dissection, the second pa-
tient developed distant metastasis detected by PET/CT at
21 months’ follow-up.
Cutaneous eyelid melanoma
In Baek et al’s series of PET/CT in patients with periorbital
malignancies, 1 patient had melanoma of the upper eyelid.42
PET/CT at initial evaluation was positive only for the primary
lesion, and the patient underwent orbital exenteration with
radiotherapy. PET/CT 15 months later successfully identified
local recurrence also detected by clinical examination, which
indicates that PET/CT did not offer any additional benefit to
conventional follow-up methods. In a series of PET/CT for
staging in a series of 250 patients with cutaneous melanoma
in all anatomic locations, PET/CT identified more metastases
than either PET or CT alone.44 In a series of 78 patients with
cutaneous melanoma in all anatomic locations, PET/CT was
95% sensitive and 95% specific in the detection of regional
or distant metastases.45 This series reported 2 false-negative
events and 2 false-positive events.
Merkel cell carcinoma
Our literature review returned no articles on the use of
PET/CT in eyelid Merkel cell carcinoma. A retrospective re-
view of 6 patients with Merkel cell carcinoma in all anatomic
locations showed that PET/CT successfully identified 9 of 10
Merkel cell carcinoma lesions confirmed by physical examina-
tion or histopathologic analysis.46 There was 1 false-positive
event and 1 false-negative event. All Merkel cell carcinoma
lesions demonstrated relatively intense FDG uptake. Given
the typical rapid rate of growth and aggressive metastatic
behavior of Merkel cell carcinoma, PET/CT has the potential
to rule out or rule in systemic sites of metastasis (Fig. 2).
Squamous cell carcinoma
There is limited literature on PET/CT for eyelid or conjunc-
tival squamous cell carcinoma (SCC). One case report high-
Figure 2. PET/CT findings in a patient with Merkel cell carcinoma of the
eyelid. (A) FDG uptake in the upper eyelid. (B) FDG uptake in the parotid
nodal basin. The patient also had a palpable mass in the parotid. PET/CT
was ordered to rule out other sites of distant metastasis.
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creased FDG uptake in retromandibular, mediastinal, and
abdominal lymph nodes.47 Biopsy of the mediastinal lymph
nodes showed inflammation only, and no biopsy was per-
formed of the retromandibular lymph node, which was found
to contain metastatic SCC on follow-up PET/CT performed
11 months later, after the node became clinically palpable.
This case report illustrates that PET/CT is able to identify
both primary conjunctival SCC and regional metastasis, but
the report does not show a higher rate of detection of nodal
metastasis with PET/CT than with clinical examination or
other conventional modalities, such as ultrasonography or
conventional CT.
PET/CT, however, may have value in detecting distant
metastasis associated with SCC. In a series of 82 patients with
recurrent SCC of the head and neck, PET/CT correctly iden-tified distant metastasis in 12 of 14 patients (86%) with dis-
tant metastasis, and PET/CT was found to be 86% sensitive
and 84% specific for the detection of distant metastasis.48
In a case-control study of 58 patients with head and neck
SCC who underwent both surgery and adjuvant radiotherapy
and/or chemotherapy, patients whose disease was initially
staged using PET/CT had a significant survival benefit com-
pared to patients for whom PET/CT was not used.49
Adenoid cystic carcinoma of the lacrimal gland
Wild et al. reported on the value of PET/CT in restaging of
3 poorly differentiated adenoid cystic carcinomas of the lac-
rimal gland.50 In 1 patient, PET/CT successfully identified his-
tologically confirmed local recurrence that was missed on
MRI; in a second patient, PET/CT missed a local recurrence
that was clearly identified on MRI.
In the initial evaluation of an adenoid cystic carcinoma of
the lacrimal gland in Baek et al’s series, PET/CT identified
both the primary lesion and distant metastasis.42 In follow-
up evaluation of an adenoid cystic carcinoma of the upper
eyelid, PET/CT successfully identified both regional and dis-
tant metastases.
Challenges in the use of PET/CT
PET/CT is a sensitive method for detecting metabolically
active foci, but it may not be as specific for cancer since
PET/CT shows uptake in benign infectious and inflammatory
lesions and fractures as well as in foci of malignancy. Because
PET/CT allows more accurate localization than PET alone,
with PET/CT it is possible to detect involvement of the con-
junctiva, lacrimal gland, extraocular muscles, and eyelid.35
However, care must be taken when evaluating orbital lesions
with PET/CT because extraocular muscles and lacrimal glands
exhibit some background FDG uptake, making it potentially
difficult to distinguish normal background uptake from tumor
uptake.
The lack of specificity of PET/CT for malignant cells in-
creases the risk for false-positive events. Studies on the spec-
ificity of PET/CT in the evaluation of ocular and orbital tumors
include a study of uveal melanoma in which PET/CT was used
to successfully differentiate benign from malignant lesions by
comparing glucose uptake values and SUVs between lesions
and the surrounding tissues.11 In this study, PET/CT was able
to increase the number of definite benign or malignant le-
sions by differentiating physiological variants from true
malignancy.
The level of uptake of FDG depends on a variety of fac-
tors, including tumor size, metabolic activity, surrounding
background activity, and serum glucose level. Different types
of tumors demonstrate different FDG uptake ranges; tumors
such as low-grade MALT lymphoma and retinoblastoma have
been shown to be poorly responsive to FDG, but the degree
of uptake of FDG varies by tumor type and individual
tumor.13,51
Cost and time investment associated with PET/CT
A main concern regarding the routine use of PET/CT is its
high cost, which is likely institution dependent but is typically
more than the cost of conventional screening methods such
as physical examination with palpation of lymph nodes,
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addition, PET/CT requires more time than conventional CT.
Proponents of PET/CT argue that the cost is justified because
the early detection of metastatic lesions allows for the forma-
tion of more appropriate treatment plans and could prevent
futile treatment, thus reducing cost in the long term. Further-
more, PET/CT offers comprehensive imaging of the entire
body in a single study, as opposed to separate CT scans with
contrast or MRI scans of multiple sites. Accurate characteriza-
tion of the true cost-benefit ratio of PET/CT versus conven-
tional screening methods is difficult because follow-up
regimens, and hence cost, likely vary widely by type, grade,
and stage of tumor and by the institution where treatment
was delivered.
Currently, Medicare coverage for PET/CT includes the ini-
tial treatment, or diagnosis and staging, and subsequent
treatment, or restaging and monitoring, for lymphoma, mel-
anoma, and head and neck tumors (not including thyroid or
central nervous system tumors) as well as for all other solid
tumors, except that Medicare does not cover PET/CT for
the initial staging of melanoma for the sole purpose of eval-
uating regional lymph nodes.52Conclusion
FDG PET/CT is an emerging diagnostic imaging modality
for diagnosis, staging, and assessment of response to ther-
apy for ocular and orbital tumors. The use of PET/CT for
detecting primary ocular or orbital lesions does not seem
to provide an advantage over and above clinical ophthalmo-
logic examination or other conventional imaging studies such
as CT or MRI of the orbit. For assessment of regional lymph
node metastasis associated with eyelid and adnexal tumors,
to date there are no studies suggesting that PET/CT is more
sensitive than conventional CT, ultrasonography, or sentinel
lymph node biopsy. However, PET/CT can detect distant
metastatic lesions that would be missed on conventional
imaging. For orbital lymphoma and OAL, use of PET/CT
has been proven to be feasible and is now accepted both
as a standard part of the initial staging work-up and for the
assessment of response to therapy. For other ophthalmic tu-
mors, PET/CT seems most appropriate for advanced cancers
of the orbit, eyelid, and eye for which the risk of distant
metastasis is high and for which the early detection of distant
sites of metastasis with 1 comprehensive study may be pref-
erable to performing multiple CT scans with contrast.
For FDG PET/CT to become an established technique in
ophthalmic oncology, larger randomized prospective studies
are needed to confirm the sensitivity and specificity of PET/
CT for different ocular and orbital tumors as well as to com-
pare PET/CT to other imaging modalities.Conflicts of interest
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